ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for critical materials production, today hosts its inaugural Capital Markets Day in London. Management will outline the Company's strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and will provide an overview of the building blocks supporting the Company’s long-term growth potential.

Over the past 12 months, the Company has moved from development into early commercialization across several of its businesses. At today's event, management intends to provide a summary of what has been achieved to date, target milestones for the next 12 months, and how the complementary businesses are building a pathway toward the Company's longer-term EBITDA goal. The presentation builds on the Company’s shareholder letter published on dated August 4, 2026 (here).

Paul Mann, Executive Chairman and Chief Executive Officer of ASP Isotopes, said:

"2026 is the year we are transitioning from building to producing. We have made steady progress towards the targets we have set out publicly. Over the next 12 months, we expect to further advance in two meaningful ways. First, increasing our revenues—from the expected production of liquid helium as Phase 1 is completed and the continued growth of our radiopharmacies. Second, growing our customer base—as we expect to make our first commercial shipments from our stable isotope division. Each of these is a step toward the more than $300 million of EBITDA that we are targeting in 2031. In addition, we are continuing to pursue public listings of Quantum Leap Energy and Noble Africa as separate public companies.